BRAF and Langerhans cell histiocytosis: Uniqueness: First BRAF-targeted therapy in Brazilian LCH, Significance: Validates vemurafenib for refractory cases, Limitations: Pediatric focus; unknown long-term effects, Recommendation: routine BRAF testing in refractory LCH